A case study from Graz highlights the role of molecular tumor boards in complex NSCLC therapy decisions. Clemens Aigner from MedUni Vienna discussed innovative approaches, including targeted treatment combinations and surgical solutions, with other experts.
» JATROS Hämatologie; Onkologie // 12.05.2026 (article in German)